Freelite®

Freelite provides prognostic information to identify patients with a higher risk of a poor outcome. These patients may need more frequent monitoring. Serum k and λ free light chains (FLCs) can predict outcomes, both from baseline tests at diagnosis and during monitoring, in many symptomatic and asymptomatic plasma cell disorders.

International Myeloma Working Group guidelines recommend the use of the serum FLC assay in prognosis - “The serum FLC assay should be measured at diagnosis for all patients with MGUS, smoldering or active multiple myeloma, solitary plasmacytoma and AL amyloidosis.”

Freelite risk stratification allows identification of patient sub groups that could benefit from different care:

• MGUS (Monoclonal Gammopathy of Undetermined Significance)
• Smouldering Multiple Myeloma
• Multiple Myeloma
• AL amyloidosis

Risk factors:

• Abnormal FLC ratio
• Serum monoclonal protein >15g/L
• IgA or IgM monoclonal protein type

Para otimizar o aconselhamento e o acompanhamento, as normas do IMWG recomendam a estratificação dos riscos dos doentes de GMSI na fase de diagnóstico utilizando o Freelite (a par de SPE/IFE). Ao identificar os que têm um risco baixo (~40%), o Freelite permite poupar tempo, dinheiro e o doente em termos de desconforto, pois serão necessários menos visitas à clínica e menos testes.

A supressão do par pelo Hevylite é também um fator de risco independente para a progressão de GMSI.